ArticleCurrent topics in microbiology and immunology2021
Murine Models for the Investigation of Colonization Resistance and Innate Immune Responses in Campylobacter Jejuni Infections.
Article in Current topics in microbiology and immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 27 citations in OpenAlex.
- Broad-spectrum phage cocktail targetingFrontiers in microbiology · 2026Article
- ComparingGut microbes · 2025Article
- Differential antibiosis predisposes mice to Campylobacter jejuni infection: Deeper insights into the impact of the gut microbiota composition in colonization resistance.European journal of microbiology & immunology · 2025Article
- Therapeutic and protective approaches to combatFrontiers in pharmacology · 2025Review
- Therapeutic effects of oral benzoic acid application during acute murine campylobacteriosis.European journal of microbiology & immunology · 2024Article
- Clustering of Gastrointestinal Microorganisms in Human Stool Samples from Ghana.Pathogens (Basel, Switzerland) · 2024Article
- Campylobacteriosis and Control Strategies againstJournal of microbiology and biotechnology · 2024Review
- Carvacrol prophylaxis improves clinical outcome and dampens apoptotic and pro-inflammatory immune responses upon Campylobacter jejuni infection of human microbiota-associated IL-10-/- mice.European journal of microbiology & immunology · 2024Article
- Article
- Prophylactic Oral Application of Activated Charcoal Mitigates Acute Campylobacteriosis in Human Gut Microbiota-Associated IL-10Biomolecules · 2024Article
- Oral curcumin ameliorates acute murine campylobacteriosis.Frontiers in immunology · 2024Article
- Prophylactic oral application of resveratrol to alleviate acute campylobacteriosis in human gut microbiota associated IL-10-/- mice.European journal of microbiology & immunology · 2023Article
- Campylobacter in Africa - A specific viewpoint.European journal of microbiology & immunology · 2023Review
- Evolution and Role of Proteases inBiomolecules · 2023Review
- Therapeutic Oral Application of Carvacrol Alleviates Acute Campylobacteriosis in Mice Harboring a Human Gut Microbiota.Biomolecules · 2023Article
- Metabolomic signatures of intestinal colonization resistance againstFrontiers in microbiology · 2023Article
- Iron Deprivation by Oral Deferoxamine Application Alleviates Acute Campylobacteriosis in a Clinical MurineBiomolecules · 2022Article
- Less Pronounced Immunopathological Responses Following Oral Butyrate Treatment ofMicroorganisms · 2022Article
- Disease-Alleviating Effects of Peroral Activated Charcoal Treatment in Acute Murine Campylobacteriosis.Microorganisms · 2021Article
- Immune-Modulatory Effects upon Oral Application of Cumin-Essential-Oil to Mice Suffering from Acute Campylobacteriosis.Pathogens (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human infections with the food-borne pathogen Campylobacter jejuni are progressively increasing worldwide and constitute a significant socioeconomic burden to mankind. Intestinal campylobacteriosis in humans is characterized by bloody diarrhea, fever, abdominal pain, and severe malaise. Some individuals develop chronic post-infectious sequelae including neurological and autoimmune diseases such as reactive arthritis and Guillain-Barré syndrome. Studies unraveling the molecular mechanisms underlying campylobacteriosis and post-infectious sequelae have been hampered by the scarcity of appropriate experimental in vivo models. Particularly, conventional laboratory mice are protected from C. jejuni infection due to the physiological colonization resistance exerted by the murine gut microbiota composition. Additionally, as compared to humans, mice are up to 10,000 times more resistant to C. jejuni lipooligosaccharide (LOS) constituting a major pathogenicity factor responsible for the immunopathological host responses during campylobacteriosis. In this chapter, we summarize the recent progress that has been made in overcoming these fundamental obstacles in Campylobacter research in mice. Modification of the murine host-specific gut microbiota composition and sensitization of the mice to C. jejuni LOS by deletion of genes encoding interleukin-10 or a single IL-1 receptor-related molecule as well as by dietary zinc depletion have yielded reliable murine infection models resembling key features of human campylobacteriosis. These substantial improvements pave the way for a better understanding of the molecular mechanisms underlying pathogen-host interactions. The ongoing validation and standardization of these novel murine infection models will provide the basis for the development of innovative treatment and prevention strategies to combat human campylobacteriosis and collateral damages of C. jejuni infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.